Alteogen Deal History & Licensing Activity
Alteogen is a biotech headquartered in Israel. Over the past three years, Alteogen has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (7 deals).
Deals (12mo)
3
Active Trials
0
Top Modality
Other
Focus Area
Other
Alteogen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alteogen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| drug-delivery technology platform | Novartis | Other | Unknown | option | Sep 2, 2026 |
| ALT-B4 (berahyaluronidase alfa) | Undisclosed global pharmaceutical company | Other | Unknown | license | Aug 5, 2026 |
| ALT-B4 | Biogen Inc. | Other | Unknown | license | Mar 25, 2026 |
Alteogen Pipeline Focus
Therapeutic areas and modalities where Alteogen is most active based on deal history and clinical trial data.
Alteogen Strategic Signals
Key indicators of Alteogen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Alteogen's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Alteogen Licensing & Deal Activity
Alteogen is a biotech company based in Israel that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Alteogen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alteogen include Other (4 deals and trials), Neurology (2 deals and trials), and Oncology (1 deal and trial). In terms of modality, Alteogen has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alteogen and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Alteogen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.